UNIT 3.12 Cyclic Nucleotide Phosphodiesterase Assay Technology

  1. S.J. MacKenzie,
  2. S.F. Hastings,
  3. C. Wells

Published Online: 1 JUN 2010

DOI: 10.1002/0471141755.ph0312s49

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

MacKenzie, S., Hastings, S. and Wells, C. 2010. Cyclic Nucleotide Phosphodiesterase Assay Technology. Current Protocols in Pharmacology. 49:3.12:3.12.1–3.12.26.

Author Information

  1. Scottish Biomedical, Glasgow, Scotland, United Kingdom

Publication History

  1. Published Online: 1 JUN 2010
  2. Published Print: JUN 2010


Because of their critical role in modulating cellular cyclic nucleotide levels, phosphodiesterases (PDEs) are involved in many disease-related signaling pathways. The PDE family is large and diverse, with members having different tissue distribution, sub-cellular localizations, and substrate specificities. Because of these characteristics, the PDEs represent a broad group of potential drug targets. Described in the present unit are the assay development and validation procedures needed to establish a high-throughput screening system for these important enzymes. The assays provide a structured approach for determining the kinetic parameters of related enzyme families to facilitate the characterization of PDE inhibitors. Curr. Protoc. Pharmacol. 49:3.12.1-3.12.26. © 2010 by John Wiley & Sons, Inc.


  • phosphodiesterase;
  • PDE assay technologies;
  • PDE assay protocols